Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
As of today, Gilead Sciences(GILD) shares are valued at $144.81. The company's market cap stands at 180.64B, with a P/E ratio of -54.84 and a dividend yield of 2.21%.
As of 2026-08-30, Gilead Sciences(GILD) stock has fluctuated between $144.81 and $149.53. The current price stands at $144.81, placing the stock 0.0% above today's low and -3.2% off the high.
Gilead Sciences(GILD) shares are trading with a volume of 3.9M, against a daily average of 5.4M.
During the past year, Gilead Sciences(GILD) stock moved between $108.46 at its lowest and $157.29 at its peak.
During the past year, Gilead Sciences(GILD) stock moved between $108.46 at its lowest and $157.29 at its peak.
GILD News
Gilead Sciences stock has delivered very strong gains over the past few years, yet current valuation checks still suggest the shares screen as inexpensive on se...
...
The U.S. Food and Drug Administration has approved Gilead Sciences’ (GILD) oral once-daily antiviral Bixlenvo as the smallest single-tablet regimen for the trea...
Analyst ratings
77%
of 30 ratingsMore GILD News
Gilead (GILD) Sciences announced that the FDA approved Bixlenvo – bictegravir 75 mg/lenacapavir 50 mg -, the smallest once-daily single tablet regimen for the t...
Key Points The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients whose virus is already un...
Gilead Sciences (NasdaqGS:GILD) received European Commission approval for Trodelvy plus Keytruda as a first-line treatment for metastatic triple-negative breast...
Key Points Gilead reported big losses last quarter, but this could pave the way for its diversification into oncology. In the meantime, investors remain focus...
(RTTNews) - Gilead Sciences (GILD) announced the European Commission has granted marketing authorization for Trodelvy in combination with Keytruda for the treat...
Gilead (GILD) Sciences announced that the European Commission has granted marketing authorization for Trodelvy in combination with Keytruda for the treatment of...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.